KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Change in Accured Expenses: 2009-2024

Historic Change in Accured Expenses for Arbutus Biopharma (ABUS) over the last 16 years, with Dec 2024 value amounting to -$2.7 million.

  • Arbutus Biopharma's Change in Accured Expenses rose 104.07% to $145,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.9 million, marking a year-over-year decrease of 27.81%. This contributed to the annual value of -$2.7 million for FY2024, which is 52.99% up from last year.
  • Arbutus Biopharma's Change in Accured Expenses amounted to -$2.7 million in FY2024, which was up 52.99% from -$5.8 million recorded in FY2023.
  • Arbutus Biopharma's 5-year Change in Accured Expenses high stood at $5.2 million for FY2022, and its period low was -$5.8 million during FY2023.
  • In the last 3 years, Arbutus Biopharma's Change in Accured Expenses had a median value of -$2.7 million in 2024 and averaged -$1.1 million.
  • Per our database at Business Quant, Arbutus Biopharma's Change in Accured Expenses skyrocketed by 172.95% in 2022 and then plummeted by 210.39% in 2023.
  • Arbutus Biopharma's Change in Accured Expenses (Yearly) stood at $1.7 million in 2020, then climbed by 14.71% to $1.9 million in 2021, then skyrocketed by 172.95% to $5.2 million in 2022, then slumped by 210.39% to -$5.8 million in 2023, then soared by 52.99% to -$2.7 million in 2024.